On November 13, GENSCRIPT B-1K recorded an Intraday Decline of 3.39% in Regular Trading, trading at HK$30.5, with turnover of HK$269 million.
The clearest identifiable catalyst was continued market digestion of the updated US National Policy for Nucleic Acid Synthesis Screening, which remained a drag on sentiment.
Recent coverage indicated the policy was updated by the White House on November 5 and fully implemented by the US National Institutes of Health on November 6. Broker commentary said GENSCRIPT B-1K had already completed self-certification under the relevant screening framework, while revenue tied to US federally funded gene-synthesis projects accounts for only a small portion of its business. The policy tightening was described as more about procurement and certification execution than a fundamental demand or market-access shock, suggesting the latest weakness is more sentiment-driven than a sign of clear near-term operational deterioration.
(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)
Comments